Does the media favor VRCA or IKT?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Inhibikase Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VRCA or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Zentalis Pharmaceuticals' score of 0.17 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VRCA or ACB?

Verrica Pharmaceuticals currently has a consensus price target of $12.67, indicating a potential upside of 184.64%. Given Verrica Pharmaceuticals' higher probable upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer VRCA or ACB?

In the previous week, Aurora Cannabis had 6 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 7 mentions for Aurora Cannabis and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Aurora Cannabis' score of 0.18 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Verrica Pharmaceuticals (VRCA) Competitors

$4.45 -0.20 (-4.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.52 +0.07 (+1.57%)

As of 09/18/2026 07:30 PM Eastern

Compare

VRCA vs. IKT, VNDA, AMRN, ZNTL, and ACB

Should you buy Verrica Pharmaceuticals stock or one of its competitors? Verrica Pharmaceuticals's main competitors and comparable companies include Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Zentalis Pharmaceuticals (ZNTL), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Verrica Pharmaceuticals compare to Inhibikase Therapeutics?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Inhibikase Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Inhibikase Therapeutics' return on equity of -42.80% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Inhibikase Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verrica Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
Inhibikase Therapeutics	$260K	1,234.39	-$48.26M	-$0.43	N/A

Verrica Pharmaceuticals presently has a consensus target price of $12.67, indicating a potential upside of 184.64%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 134.78%. Given Verrica Pharmaceuticals' higher probable upside, equities analysts clearly believe Verrica Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Verrica Pharmaceuticals and Inhibikase Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Verrica Pharmaceuticals has higher earnings, but lower revenue than Vanda Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
Vanda Pharmaceuticals	$216.10M	1.44	-$220.47M	-$4.63	N/A

Verrica Pharmaceuticals has a net margin of -102.84% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 1 mentions for Verrica Pharmaceuticals and 0 mentions for Vanda Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Vanda Pharmaceuticals' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
Vanda Pharmaceuticals	Neutral

Verrica Pharmaceuticals presently has a consensus price target of $12.67, indicating a potential upside of 184.64%. Vanda Pharmaceuticals has a consensus price target of $13.70, indicating a potential upside of 167.06%. Given Verrica Pharmaceuticals' higher possible upside, equities analysts clearly believe Verrica Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Amarin?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals currently has a consensus price target of $12.67, indicating a potential upside of 184.64%. Amarin has a consensus price target of $13.00, indicating a potential downside of 4.62%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Amarin has a net margin of -14.56% compared to Verrica Pharmaceuticals' net margin of -102.84%. Amarin's return on equity of -0.20% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Amarin	-14.56%	-0.20%	-0.14%

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Amarin. MarketBeat recorded 1 mentions for Verrica Pharmaceuticals and 0 mentions for Amarin. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Amarin's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
Amarin	Neutral

Verrica Pharmaceuticals has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
Amarin	$213.65M	1.35	-$38.80M	-$0.99	N/A

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Amarin has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Summary

Verrica Pharmaceuticals beats Amarin on 11 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Zentalis Pharmaceuticals' return on equity of -70.18% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Zentalis Pharmaceuticals' score of 0.17 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Verrica Pharmaceuticals has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
Zentalis Pharmaceuticals	$67.43M	3.31	-$137.06M	-$1.95	N/A

Verrica Pharmaceuticals presently has a consensus target price of $12.67, indicating a potential upside of 184.64%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 117.04%. Given Verrica Pharmaceuticals' higher probable upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Zentalis Pharmaceuticals beats Verrica Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Aurora Cannabis?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

In the previous week, Aurora Cannabis had 6 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 7 mentions for Aurora Cannabis and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Aurora Cannabis' score of 0.18 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurora Cannabis	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Aurora Cannabis has a net margin of -32.26% compared to Verrica Pharmaceuticals' net margin of -102.84%. Aurora Cannabis' return on equity of 4.37% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Aurora Cannabis	-32.26%	4.37%	3.45%

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Verrica Pharmaceuticals has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
Aurora Cannabis	$247.82M	1.01	-$88.13M	-$1.41	N/A

Verrica Pharmaceuticals currently has a consensus price target of $12.67, indicating a potential upside of 184.64%. Given Verrica Pharmaceuticals' higher probable upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Aurora Cannabis beats Verrica Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$76.45M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-2.66	797.25	275.49	25.40
Price / Sales	2.15	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	2.87	10.53	10.46	6.33
Net Income	-$17.89M	$2.82B	$3.49B	$358.33M
7 Day Performance	-9.37%	1.69%	0.59%	1.12%
1 Month Performance	-8.44%	0.24%	-1.74%	-2.39%
1 Year Performance	1.37%	3.95%	18.13%	5.35%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	4.5565 of 5 stars	$4.45 -4.3%	$12.67 +184.6%	+1.4%	$76.45M	$35.58M	N/A	76	Positive News
IKT Inhibikase Therapeutics	1.5646 of 5 stars	$2.39 +2.1%	$5.40 +125.9%	+40.2%	$326.51M	$260K	N/A	35	News Coverage Positive News
VNDA Vanda Pharmaceuticals	2.2209 of 5 stars	$5.15 +1.2%	$13.70 +166.0%	+14.3%	$307.76M	$216.10M	N/A	533	Positive News
AMRN Amarin	0.9372 of 5 stars	$14.00 +1.4%	$13.00 -7.1%	-11.2%	$291.49M	$213.65M	N/A	80
ZNTL Zentalis Pharmaceuticals	3.5052 of 5 stars	$3.50 -0.3%	$6.75 +92.9%	+104.6%	$251.57M	$67.43M	N/A	160	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. IKT, VNDA, AMRN, ZNTL, and ACB

How does Verrica Pharmaceuticals compare to Inhibikase Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Summary

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. IKT, VNDA, AMRN, ZNTL, and ACB

How does Verrica Pharmaceuticals compare to Inhibikase Therapeutics?

Is VRCA or IKT more profitable?

Which has more risk & volatility, VRCA or IKT?

Does the media favor VRCA or IKT?

Which has stronger earnings & valuation, VRCA or IKT?

Do analysts recommend VRCA or IKT?

Do institutionals and insiders have more ownership in VRCA or IKT?

Summary

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Which has stronger valuation and earnings, VRCA or VNDA?

Is VRCA or VNDA more profitable?

Does the media favor VRCA or VNDA?

Do analysts rate VRCA or VNDA?

Which has more volatility and risk, VRCA or VNDA?

Do institutionals & insiders have more ownership in VRCA or VNDA?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Do institutionals and insiders have more ownership in VRCA or AMRN?

Do analysts rate VRCA or AMRN?

Is VRCA or AMRN more profitable?

Does the media favor VRCA or AMRN?

Which has better earnings & valuation, VRCA or AMRN?

Which has more volatility & risk, VRCA or AMRN?

Summary

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Which has more risk & volatility, VRCA or ZNTL?

Is VRCA or ZNTL more profitable?

Does the media prefer VRCA or ZNTL?

Do insiders and institutionals believe in VRCA or ZNTL?

Which has better valuation and earnings, VRCA or ZNTL?

Do analysts prefer VRCA or ZNTL?

Summary

How does Verrica Pharmaceuticals compare to Aurora Cannabis?

Which has more volatility and risk, VRCA or ACB?

Does the media prefer VRCA or ACB?

Is VRCA or ACB more profitable?

Do institutionals & insiders believe in VRCA or ACB?

Which has stronger earnings & valuation, VRCA or ACB?

Do analysts recommend VRCA or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools